Oxis names new directors to its board.PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 31, 1996--OXIS International Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :OXIS) announced the addition of two members to its board of directors. "Jim McCamant, biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. industry analyst, and Stuart Lang, CPA (Computer Press Association, Landing, NJ) An earlier membership organization founded in 1983 that promoted excellence in computer journalism. Its annual awards honored outstanding examples in print, broadcast and electronic media. The CPA disbanded in 2000. , The Lang Group, enhance the board's knowledge in all aspects of the pharmaceutical sector and of corporate finance," said Ray R. Rogers, chairman. "Their assistance will be invaluable as we plan and move our products and research into the marketplace." McCamant, age 62, has more than 30 years experience in the investment field. He is the founder and editor of the widely referenced Medical Technology Stock Letter, which provides expert analysis of developments and investment opportunities in medical biotechnology. McCamant is a general partner of the American Health Care Fund, LP. During his 25-year career, Lang, age 59, specializes in strategic business planning and mergers and acquisitions, for a variety of industries, both public and private. Lang served as an instructor in financial forecasting, taxation and business management. He is past chairman of AI International and managing partner for The Lang Group, a Portland, Ore., CPA firm. Lang and McCamant will serve out the current term for retiring members Peter E. Taussig and Lawrance A. Brown and stand for election at the company's mid-year annual meeting. OXIS International is a drug development and diagnostic company dedicated to the research and development of technologies and products to combat diseases associated with free radicals and reactive oxygen species reactive oxygen species, n molecules and ions of oxygen that have an unpaired electron, thus rendering them extremely reactive. Many cellular structures are susceptible to attack by ROS contributing to cancer, heart disease, and cerebrovascular disease. (ROS ROS, n.pr See reactive oxygen species. ). The company has headquarters in Portland, with research facilities outside Paris. CONTACT: OXIS International Inc. Claudia Groth, 503/283-3911 OR KVO KVO Keep Vein Open KVO Key-Value Observing KVO Kunstvakonderwijs (Dutch) KVO Keeler, Vandyke, O'Brien (KVO Industries; Santa Rosa CA) Will Anderson, 503/221-1551 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion